Analysis of p21(WAF1/CIP1) in primary bladder tumors

Oncology Research

Volumn 8, Issue 10-11, 1996, Pages 409-414

  Lacombe, Louis ^a   Orlow, Irene ^a   Silver, David ^a   Gerald, William L ^a   Fair, William R ^a   Reuter, Victor E ^a   Cordon Cardo, Carlos ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

bladder cancer; p21(WAF1 CIP1); transitional cell carcinoma; urinary bladder

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GENETICS; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; BIOSYNTHESIS; BLADDER TUMOR; CELL CYCLE; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PHYSIOLOGY; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DNA;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, NEOPLASM; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; URINARY BLADDER NEOPLASMS;

EID: 0030320521     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. 1. Xiong, Y.; Hannon, G. J.; Zhang, H.; Casso, D.; Kobayashi, R.; Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704; 1993.
2. 1 cyclin-dependent kinases. Cell 75:805-816; 1993.
3. 3. El-Deiry, W. S.; Tokino, T.; Velculescu, V. E.; Levy, D. B.; Parsons, R.; Trent, J. M.; Lin, D.; Mercer, W. E.; Kinzler, K. W.; Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825; 1993.
4. 1 arrest. Cell 76:1013-1023; 1994.
5. 5. Macleod, K. F.; Sherry, N.; Hannon, G.; Beach, D.; Tokino, T.; Kinzler, K.; Vogelstein, B.; Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9:935-944; 1995.
6. 6. Bathia, K.; Fan, S.; Spangler, G.; Weintraub, M.; O'Connor, P. M.; Judde, J.-G.; Magrath, I. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res. 55:1431-1435; 1995.
7. 7. Vidal, M. J.; Loganzo F. Jr.; de Oliveira, A. R.; Hayward, N. K.; Albino, A. P. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res. 5:243-250; 1995.
8. 8. Gao, X.; Chen, Y. Q.; Wu, N.; Grignon, D. J.; Sakr, W.; Porter, A. T.; Honn, K. V. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11:1395-1398; 1995.
9. 9. Shiohara, M.; El-Deiry, W. S.; Wada, M.; Nakamaki, T.; Takeuchi, S.; Yang, R.; Chen, D.-L.; Vogelstein, B.; Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781-3784; 1994.
10. 10. Li, Y-J.; Laurent-Puig, P.; Salmon, R. J.; Thomas, G.; Hamelin, R. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 10:599-601; 1995.
11. 11. Reuter, V. E.; Melamed, M. R. The lower urinary tract. In: Sternberg, S. S., ed. Diagnostic surgical pathology. New York: Raven Press, Ltd.; 1994:pp. 1767-1805.
12. 12. Dalbagni, G.; Presti, J. C., Jr.; Reuter, V. E.; Zhang, Z.-F.; Sarkis, A. S.; Fair, W. R.; Cordon-Cardo, C. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diag. Mol. Pathol. 2:4-13; 1993.
13. 13. Orita, M.; Iwahana, H.; Kanazawa, H.; Hayashi, K.; Sekiya, T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. USA 86: 2766-2770; 1989.
14. 14. Sanger, F.; Nicklen, S.; Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467; 1977.
15. 15. Sarkis, A. S.; Dalbagni, G.; Cordon-Cardo, C.; Melamed, J.; Zhang, Z.-F.; Sheinfeld, J.; Fair, W. R.; Herr, H. W.; Reuter, V. E. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol. 152:388-392, 1994.
16. 16. Kamb, A.; Liu, Q.; Harshman, K.; Tavtigian, S.; Cordon-Cardo, C.; Skolnick, M. H. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415-417; 1994.
17. 17. Jen, J.; Harper, J. W.; Bigner, S. H.; Bigner, D. D.; Papadopoulos, N.; Markowitz, S.; Wilson, J. K. V.; Kinzler, K. W.; Vogelstein, B. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54:6353-6358; 1994.
18. 18. Gruis, N. A.; Weaver-Feldhaus, J.; Eeles, R.; Liu, Q.; Frye, C.; Orlow, I.; Lacombe, L.; Ponce, V.; Lianes, P.; Latres, E.; Skolnick, M.; Cordon-Cardo, C.; Kamb, A. The MTS1 and TP53 genes may involve separate pathways of tumorigenesis. Am. J. Pathol. 146:1199-1206; 1995.
19. (MTS2/INK4B) in human bladder tumors. J. Natl. Cancer Inst. 87:1524-1529; 1995.
20. 20. Ravnik-Glavac, M.; Glavac, D.; Dean, M. Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene. Hum. Mol. Genet. 3:801-807; 1994.
21. 21. Cordon-Cardo, C.; Dalbagni, G.; Saez, G. T.; Oliva, M. R.; Zhang, Z.-F.; Rosai, J.; Reuter, V. E.; Pellicer, A. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer 56:347-353; 1994.
22. 22. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 mutations in human cancers. Science 253:49-53; 1991.
23. 23. Gutierrez, M.; Bhatia, K.; Diez, B.; Sackman, M. F.; Epelman, S.; De Andreas, M. L.; Huppi, K.; Magrath, I. Prognostic significance of p53 mutations in small noncleaved cell lymphomas. Int. J. Oncol. 4:567-571; 1994.
24. 24. Sarkis, A. S.; Zhang, Z.-F.; Cordon-Cardo, C.; Melamed, J.; Dalbagni, G.; Sheinfeld, J.; Fair, W. R.; Herr, H. W.; Reuter, V. E. p53 nuclear overexpression and disease progression in Ta bladder carcinoma. Int. J. Oncol. 3:355-360; 1993.
25. 25. Sarkis, A. S.; Dalbagni, G.; Cordon-Cardo, C.; Zhang, Z.-F.; Sheinfeld, J.; Fair, W. R.; Herr, H. W.; Reuter, V. E. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker of disease progression. J. Natl. Cancer Inst. 85:53-59; 1993.
26. 26. Esrig, D.; Elmajian, D.; Groshen, S.; Freeman, J. A.; Stein, J. P.; Chen, S.-C.; Nichols, P. W.; Skinner, D. G.; Jones, P. A.; Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331:1259-1264; 1994.